• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Corrigendum to 'MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC' [Journal of Thoracic Oncology 19 Issue 3 (2024) 434-450].

作者信息

Haratake Naoki, Ozawa Hiroki, Morimoto Yoshihiro, Yamashita Nami, Daimon Tatsuaki, Bhattacharya Atrayee, Wang Keyi, Nakashoji Ayako, Isozaki Hideko, Shimokawa Mototsugu, Kikutake Chie, Suyama Mikita, Hashinokuchi Asato, Takada Kazuki, Takenaka Tomoyoshi, Yoshizumi Tomoharu, Mitsudomi Tetsuya, Hata Aaron N, Kufe Donald

机构信息

Department of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts.

Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.

出版信息

J Thorac Oncol. 2025 Mar;20(3):399. doi: 10.1016/j.jtho.2024.12.004. Epub 2024 Dec 18.

DOI:10.1016/j.jtho.2024.12.004
PMID:39692639
Abstract
摘要

相似文献

1
Corrigendum to 'MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC' [Journal of Thoracic Oncology 19 Issue 3 (2024) 434-450].《“MUC1-C是NSCLC中获得性奥希替尼耐药的常见驱动因素”的勘误》[《胸部肿瘤学杂志》第19卷第3期（2024年）434 - 450页]
J Thorac Oncol. 2025 Mar;20(3):399. doi: 10.1016/j.jtho.2024.12.004. Epub 2024 Dec 18.
2
MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC.MUC1-C是NSCLC中获得性奥希替尼耐药的常见驱动因素。
J Thorac Oncol. 2024 Mar;19(3):434-450. doi: 10.1016/j.jtho.2023.10.017. Epub 2023 Nov 3.
3
Corrigendum to 'Even With the CROWN Findings, There Remain Multiple First-Line Treatment Options for Patients With Advanced ALK-Positive NSCLC' [Journal of Thoracic Oncology Volume 20 Issue 2 (2025) 150-153].《“即便有CROWN研究结果，晚期ALK阳性非小细胞肺癌患者仍有多种一线治疗选择”的勘误》[《胸部肿瘤学杂志》第20卷第2期（2025年）150 - 153页]
J Thorac Oncol. 2025 May;20(5):680. doi: 10.1016/j.jtho.2025.02.006. Epub 2025 Feb 21.
4
Comment on "MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC".对“MUC1-C是NSCLC中获得性奥希替尼耐药的常见驱动因素”的评论
J Thorac Oncol. 2024 Dec;19(12):e87-e88. doi: 10.1016/j.jtho.2024.08.012.
5
Comment on "MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC".对“MUC1-C是NSCLC中获得性奥希替尼耐药的常见驱动因素”的评论
J Thorac Oncol. 2024 Dec;19(12):e88-e89. doi: 10.1016/j.jtho.2024.08.016.
6
Never-smoking nonsmall cell lung cancer as a separate entity: clinicopathologic features and survival.从不吸烟的非小细胞肺癌作为一个独立实体：临床病理特征与生存情况
Cancer. 2008 Sep 1;113(5):1012-8. doi: 10.1002/cncr.23679.
7
Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.针对 c-Myc 克服第三代 EGFR 酪氨酸激酶抑制剂奥希替尼治疗 EGFR 突变型 NSCLC 获得性耐药。
Cancer Res. 2021 Sep 15;81(18):4822-4834. doi: 10.1158/0008-5472.CAN-21-0556. Epub 2021 Jul 21.
8
Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR-mutant NSCLC patient with acquired LMNA-NTRK1 fusion following osimertinib resistance.奥希替尼耐药后，联合使用奥希替尼再挑战和恩曲替尼对一名获得性LMNA-NTRK1融合的EGFR突变非小细胞肺癌患者的生存获益。
Respirol Case Rep. 2022 Oct 17;10(11):e01054. doi: 10.1002/rcr2.1054. eCollection 2022 Nov.
9
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.一项比较奥希替尼联合贝伐珠单抗与奥希替尼单药二线治疗表皮生长因子受体（EGFR）阳性且获得性 T790M 突变的晚期非小细胞肺癌（NSCLC）的随机 II 期研究：欧洲胸部肿瘤平台（ETOP）10-16 BOOSTER 试验。
Ann Oncol. 2022 Feb;33(2):181-192. doi: 10.1016/j.annonc.2021.11.010. Epub 2021 Nov 26.
10
Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.胰岛素样生长因子-1 受体的激活赋予 EGFR T790M 突变的非小细胞肺癌对奥希替尼的获得性耐药。
Thorac Cancer. 2020 Jan;11(1):140-149. doi: 10.1111/1759-7714.13255. Epub 2019 Nov 22.

引用本文的文献

1
Mucin-1: a promising pan-cancer therapeutic target.粘蛋白-1：一个有前景的泛癌治疗靶点。
NPJ Precis Oncol. 2025 Jul 2;9(1):218. doi: 10.1038/s41698-025-01016-2.
2
MUC1-C dependency in drug resistant HR+/HER2- breast cancer identifies a new target for antibody-drug conjugate treatment.耐药性 HR+/HER2- 乳腺癌中 MUC1-C 的依赖性确定了抗体药物偶联物治疗的新靶点。
NPJ Breast Cancer. 2025 Apr 26;11(1):39. doi: 10.1038/s41523-025-00751-w.